Section 32 Fund 3, LP - Aug 5, 2021 Form 4 Insider Report for DA32 Life Science Tech Acquisition Corp. (DALS)

Signature
/s/ Henrikki Harsu, Attorney-in-Fact for Section 32 Fund 3, LP
Stock symbol
DALS
Transactions as of
Aug 5, 2021
Transactions value $
$0
Form type
4
Date filed
8/9/2021, 09:54 PM
Previous filing
Aug 3, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DALS Class B Common Stock, par value $0.0001 per share Disposed to Issuer $0 -701K -13% $0.00 4.7M Aug 5, 2021 Class A Common Stock 701K Through DA32 Sponsor LLC F1, F2, F3, F4
transaction DALS Class B Common Stock, par value $0.0001 per share Disposed to Issuer $0 -30K -0.64% $0.00 4.67M Aug 5, 2021 Class A Common Stock 30K Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 File No. 333-257679) (the "Registration Statement") and have no expiration date.
F2 On August 5, 2021, DA32 Sponsor LLC ("Sponsor") forfeited 701,250 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO.
F3 This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F4 Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor.
F5 On August 5, 2021, the Reporting Persons forfeited 30,000 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Persons' control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the IPO disclosing all material information about the Issuer and the IPO.

Remarks:

See Exhibit 99.1 - Joint Filer Information, which is incorporated herein by reference and describes in further detail the relationships of the Reporting Persons to the Issuer. Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24.1, 24.2 and 24.3 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by Section 32 Fund 3, LP, Section 32 GP 3, LLC and William J Maris. Steve Kafka, an employee of Section 32 Fund 3, LP, serves as a director of the Issuer.